937 related articles for article (PubMed ID: 26909474)
1. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine.
Oliveira-Barros EG; Nicolau-Neto P; Da Costa NM; Pinto LFR; Palumbo A; Nasciutti LE
Cell Biol Int; 2017 Nov; 41(11):1239-1245. PubMed ID: 28477422
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for DNA repair-deficient prostate cancer.
Teply BA; Antonarakis ES
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
[TBL] [Abstract][Full Text] [Related]
4. Future directions for precision oncology in prostate cancer.
Mizuno K; Beltran H
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S86-S96. PubMed ID: 35657153
[TBL] [Abstract][Full Text] [Related]
5. [Molecular tumor board prostate cancer].
Seitz AK; Heck MM; Kamer MW; Grüllich C
Urologe A; 2019 Jul; 58(7):752-759. PubMed ID: 31049637
[TBL] [Abstract][Full Text] [Related]
6. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
7. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
8. Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer.
Fraser M; Berlin A; Bristow RG; van der Kwast T
Urol Oncol; 2015 Feb; 33(2):85-94. PubMed ID: 24768356
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibition in castration-resistant prostate cancer.
Nappi L; Gleave ME
Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
[No Abstract] [Full Text] [Related]
10. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
11. Towards precision oncology in advanced prostate cancer.
Ku SY; Gleave ME; Beltran H
Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
[TBL] [Abstract][Full Text] [Related]
12. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
Buonerba C; Di Lorenzo G; Sonpavde G
Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
[TBL] [Abstract][Full Text] [Related]
13. The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.
Hovelson DH; Tomlins SA
Cancer J; 2016; 22(5):357-361. PubMed ID: 27749331
[TBL] [Abstract][Full Text] [Related]
14. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
[TBL] [Abstract][Full Text] [Related]
15. Integrating Novel Targets and Precision Medicine Into Prostate Cancer Care-Part 1: The Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Mar; 33(3):113-8. PubMed ID: 30866035
[TBL] [Abstract][Full Text] [Related]
16. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
17. Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Palmbos PL; Hussain MH
Oncology (Williston Park); 2016 May; 30(5):377-85. PubMed ID: 27188668
[TBL] [Abstract][Full Text] [Related]
18. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
19. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
20. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
